Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 50.41M | 56.96M | 56.13M | 52.62M | 51.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.41M | 56.96M | 56.13M | 52.62M | 51.07M |
| Cost of Revenue | 525.80M | 485.89M | 459.49M | 450.97M | 325.66M |
| Gross Profit | -475.38M | -428.93M | -403.36M | -398.35M | -301.96M |
| SG&A Expenses | 512.13M | 480.76M | 452.16M | 450.45M | 280.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04B | 966.65M | 911.65M | 901.42M | 868.03M |
| Operating Income | -987.52M | -909.69M | -855.52M | -848.79M | -816.96M |
| Income Before Tax | -669.99M | 4.72B | 4.70B | 4.48B | 4.67B |
| Income Tax Expenses | -10.10M | 37.83M | 28.61M | 18.32M | 27.28M |
| Earnings from Continuing Operations | -659.89 | 4.68K | 4.67K | 4.46K | 4.64K |
| Earnings from Discontinued Operations | 373.03M | -12.51M | -55.90M | -227.61M | -227.61M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 170.23M | 142.45M | 119.50M | 117.72M | 86.34M |
| Net Income | -116.62M | 4.81B | 4.74B | 4.35B | 4.47B |
| EBIT | -987.52M | -909.69M | -855.52M | -848.79M | -816.96M |
| EBITDA | -973.48M | -895.08M | -837.30M | -829.62M | -797.06M |
| EPS Basic | -0.14 | 5.99 | 5.91 | 5.40 | 5.54 |
| Normalized Basic EPS | -0.39 | -0.38 | -0.41 | -0.48 | -0.35 |
| EPS Diluted | -0.15 | 5.65 | 5.56 | 5.05 | 5.20 |
| Normalized Diluted EPS | -0.39 | -0.37 | -0.41 | -0.48 | -0.35 |
| Average Basic Shares Outstanding | 3.00B | 3.07B | 3.11B | 3.13B | 3.04B |
| Average Diluted Shares Outstanding | 3.00B | 3.12B | 3.15B | 3.18B | 3.09B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
